Jul 18, 2022 / NTS GMT
Leland James Gershell - Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst
Good afternoon, everybody, and welcome to a session here with the team from Windtree Therapeutics as well as a specialist in the area of cardiology and more specifically heart failure and cardiogenic shock, which Windtree is focusing its development efforts on. From the company, we have Craig Fraser, who is the company's Chief Executive Officer. We also have Steve Simonson, who is Chief Medical Officer.
We're also joined by Dr. Alexandre Mebazaa, who is based in Paris, where he is the Director of -- sorry, I just lost my window -- there we are. He is the Chairman of the Department of Anesthesiology and Critical Care at Hôpital Lariboisière and he's also a professor in anesthesiology and critical care medicine at the Paris Diderot School of Medicine.
So thank you for joining us. Welcome, and this should be an interesting discussion as we talk about the drug candidate, istaroxime, which has a dual mechanism of action, is being developed by Windtree for a couple of indications. I've mentioned acute
Windtree Therapeutics Inc Fireside Chat Hosted By Oppenheimer Transcript
Jul 18, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers